Meitav Dash Investments Ltd. Sells 47,042 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Meitav Dash Investments Ltd. lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO – Get Rating) by 84.9% during the fourth quarter, Holdings Channel reports. The institutional investor owned 8,394 shares of the medical research company’s stock after selling 47,042 shares during the quarter. Meitav Dash Investments Ltd.’s holdings in Thermo Fisher Scientific were worth $5,576,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of TMO. Mizuho Securities Co. Ltd. boosted its holdings in shares of Thermo Fisher Scientific by 200.0% in the 3rd quarter. Mizuho Securities Co. Ltd. now owns 45 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 30 shares during the last quarter. Widmann Financial Services Inc. acquired a new position in Thermo Fisher Scientific during the fourth quarter worth $26,000. Core Alternative Capital purchased a new stake in shares of Thermo Fisher Scientific during the third quarter worth $27,000. Costello Asset Management INC purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $33,000. Finally, Moors & Cabot Inc. grew its holdings in shares of Thermo Fisher Scientific by 319.3% during the third quarter. Moors & Cabot Inc. now owns 25,000 shares of the medical research company’s stock worth $37,000 after buying an additional 19,037 shares in the last quarter. 86.17% of the stock is currently owned by hedge funds and other institutional investors.

In other news, Director Jim P. Manzi sold 1,500 shares of the stock in a transaction on Monday, February 14th. The stock was sold at an average price of $563.95, for a total value of $845,925.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.44% of the stock is owned by corporate insiders.

Several brokerages have weighed in on TMO. StockNews.com began coverage on shares of Thermo Fisher Scientific in a research note on Thursday, March 31st. They set a “hold” rating for the company. BTIG Research reissued a “buy” rating and set a $718.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, February 3rd. Wells Fargo & Company cut shares of Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and reduced their price target for the stock from $605.00 to $525.00 in a research report on Monday. Zacks Investment Research cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and set a $609.00 target price on the stock. in a report on Monday, January 24th. Finally, Barclays started coverage on shares of Thermo Fisher Scientific in a report on Wednesday, January 26th. They issued an “overweight” rating and a $700.00 target price on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $647.00.

NYSE TMO traded up $38.38 on Thursday, reaching $558.86. The company had a trading volume of 65,828 shares, compared to its average volume of 1,633,510. The firm has a market capitalization of $218.76 billion, a PE ratio of 28.42, a P/E/G ratio of 1.84 and a beta of 0.82. Thermo Fisher Scientific Inc. has a 1 year low of $438.72 and a 1 year high of $672.34. The firm has a 50-day moving average of $564.01 and a 200-day moving average of $597.43. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.50 and a quick ratio of 1.12.

Thermo Fisher Scientific (NYSE:TMO – Get Rating) last announced its earnings results on Wednesday, February 2nd. The medical research company reported $6.54 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $5.22 by $1.32. The company had revenue of $10.70 billion for the quarter, compared to analyst estimates of $9.25 billion. Thermo Fisher Scientific had a return on equity of 26.34% and a net margin of 19.70%. Thermo Fisher Scientific’s quarterly revenue was up 1.4% on a year-over-year basis. During the same period in the prior year, the company posted $7.09 EPS. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 22.52 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, April 14th. Investors of record on Wednesday, March 16th were paid a dividend of $0.30 per share. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.26. This represents a $1.20 dividend on an annualized basis and a yield of 0.21%. The ex-dividend date of this dividend was Tuesday, March 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 6.17%.

Thermo Fisher Scientific Profile (Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Articles